Marty Makary: “When Humira had its biosimilar come out seven years later…”

“We can do that. We can talk about the merits of that, or we can create more intense competition and let the market forces do some of that. So When Humira had its biosimilar come out seven years later, it should be about two years. Or if the biosimilar starts in development earlier like it does in Europe, maybe one year or half a year. But when you have that gap, it allows, you know, a longer period of no competition.” (26:18–26:24)

This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.